Biodegradable nanoparticles are being developed to deliver two FDA-approved drugs simultaneously to treat prostate cancer.
These nanoparticles target the P-selectin protein, which is overexpressed on tumor cells, allowing for precise drug delivery to cancerous tissue while sparing healthy cells. The dual drug delivery creates a synergistic effect, which can shrink tumors more effectively, even at significantly lower doses.
This technology can penetrate the blood-brain barrier, potentially treating brain metastases associated with advanced prostate cancer. Early testing has shown improved efficacy, delayed disease progression, and a survival advantage with reduced side effects. The approach is adaptable to different drug pairs, offering hope for more precise and potent combination therapies.
This research suggests a step toward more personalized and tolerable treatments for cancer. This approach may be applicable to multiple tumor types since P-selectin is present in various cancers, including aggressive subtypes of prostate cancer. The ability to use lower doses of drugs is a significant advantage of this delivery system.
Developments in the nanoparticle world and how to determine and predict chemo benefits in MHSPC
